公开(公告)号：US20240325538A1

公开(公告)日：2024-10-03

申请号：US18254167

申请日：2021-11-25

申请人： SHANGHAI JUNCELL THERAPEUTICS CO., LTD.

发明人： Huajun JIN ,  Zhou HE ,  Tiantian LI ,  Yongchao SHEN ,  Haibin CHEN ,  Chen HUANG ,  Fuhui XU

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N5/0783

CPC分类号： A61K39/464499 ,  A61K39/4611 ,  A61P35/00 ,  C12N5/0636 ,  C12N2501/22 ,  C12N2501/2301 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2309 ,  C12N2501/231 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2318 ,  C12N2501/2321 ,  C12N2501/24 ,  C12N2501/515 ,  C12N2501/52 ,  C12N2502/30

摘要： A culture composition for expanding a TIL, containing IL-2, IL-7, IL-15, and an immune checkpoint antibody or an antigen-binding fragment thereof. The immune checkpoint antibody comprises any one or more of a PD-1 antibody, a CTLA-4 antibody, a LAG-3 antibody, a TIM-3 antibody, a TIGIT antibody, and a BTLA antibody. The present invention further relates to a TIL expanding culture medium, a method for preparing a TIL population, and a pharmaceutical composition. In the culture composition, cell proliferation and activity are ensured while greatly reducing the used amount of IL-2, and IL-2 treatment is removed after infusing the TILs obtained using the culture composition into a patient so as to reduce side effects; moreover, no feeder cells are used in an expansion process, exogenous pollution is reduced and the manufacturing process is simplified, the manufacturing costs reduced, and the manufacturing time shortened.

公开(公告)号：US20240325448A1

公开(公告)日：2024-10-03

申请号：US18702095

申请日：2023-09-28

申请人： JEROME CANADY RESEARCH INSTITUTE FOR ADVANCED BIOLOGICAL AND TECHNOLOGICAL SCIENCES

发明人： Jerome Canady ,  Saravana Murthy

IPC分类号： A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C12N5/0783 ,  C12N13/00

CPC分类号： A61K35/17 ,  A61K39/4611 ,  C07K7/06 ,  C12N5/0636 ,  C12N13/00 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/998 ,  C12N2502/30

摘要： A method to oxidize pan-cancer epitopes of COL6A3 protein (peptide sequences 1. FLLDGSANV (SEQ ID NO: 1), 2. FLLDGSEGV (SEQ ID NO: 2) and 3. FLLDGSINF (SEQ ID NO: 3)) by cold atmospheric plasma treatment for developing solid tumor cancer vaccines.

公开(公告)号：US20240271095A1

公开(公告)日：2024-08-15

申请号：US18290257

申请日：2022-05-13

申请人： Appia Bio, Inc.

发明人： Jeffrey Scott Wiezorek ,  Drake Smith ,  Xi Wang ,  Lanny Gov ,  Sean Allen

IPC分类号： C12N5/0783 ,  A01N1/02

CPC分类号： C12N5/0646 ,  A01N1/0284 ,  C12N5/0636 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/998 ,  C12N2506/03 ,  C12N2510/00

摘要： This disclosure provides methods for producing T cells with shortened ex vivo manufacturing time. In particular, this disclosure involves the production of T cells from hematopoietic stem cells with the proviso that the process does not involve subsequent in vitro steps of activation and/or expansion of the T cells.

公开(公告)号：US20240216507A1

公开(公告)日：2024-07-04

申请号：US17907180

申请日：2021-03-22

申请人： CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Catherine BOLLARD ,  Michael KELLER ,  Chris LAZARSKI ,  Allistair ABRAHAM ,  Patrick HANLEY ,  Conrad Russell Y. CRUZ

IPC分类号： A61K39/00 ,  C12N5/0783

CPC分类号： A61K39/4611 ,  A61K39/464838 ,  C12N5/0636 ,  C12N2501/2304 ,  C12N2501/2307

摘要： The invention pertains to a method for preventing or treating SARS-CoV-2 infection by administering SARS-CoV-2 specific T cells which recognize particular peptide epitopes in SARS-CoV-2 spike (S), nucleocapsid (N), membrane, and envelope proteins.

公开(公告)号：US11981923B2

公开(公告)日：2024-05-14

申请号：US17659624

申请日：2022-04-18

申请人： Baylor College of Medicine

发明人： Ann Marie Leen ,  Juan Fernando Vera Valdes ,  Cliona M. Rooney ,  Ulrike Gerdemann

IPC分类号： C12N5/0783 ,  A61K39/12 ,  C07K14/025 ,  C07K14/03 ,  C07K14/11 ,  C07K14/135 ,  C12N7/00 ,  A61K39/00

CPC分类号： C12N5/0638 ,  A61K39/12 ,  C07K14/025 ,  C07K14/03 ,  C07K14/11 ,  C07K14/135 ,  C12N7/00 ,  A61K2039/5158 ,  A61K2039/55527 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/577 ,  A61K2039/70 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2710/16134 ,  C12N2710/16234 ,  Y02A50/30

摘要： The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.

公开(公告)号：US20240100096A1

公开(公告)日：2024-03-28

申请号：US18535741

申请日：2023-12-11

申请人： ADOC SSF, LLC

发明人： Andrew Y. Hu ,  Ramya H. Tunuguntia

IPC分类号： A61K35/17 ,  C12N5/0783

CPC分类号： A61K35/17 ,  C12N5/0636 ,  A61K2039/5158 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/51 ,  C12N2501/515

摘要： The present disclosure provides novel artificial antigen presenting cells (aAPCs). The aAPCs disclosed herein comprise a liposome comprising a phospholipid and a stimulatory ligand displayed on the outer surface of the liposome. The aAPCs of the present disclosure can be used as an “off the shelf” tool to activate and expand a T cell of interest. Also, the present disclosure provides methods of activating a T cell and manufacturing a T cell therapy product using the aAPCs disclosed herein.

公开(公告)号：US20240000936A1

公开(公告)日：2024-01-04

申请号：US18310649

申请日：2023-05-02

申请人： Children's National Medical Center ,  Fred Hutchinson Cancer Center

发明人： Catherine Mary Bollard ,  Danielle Sohai ,  Conrad Russell Y. Cruz ,  Thomas Uldrick

IPC分类号： A61K39/00 ,  C12N5/0783 ,  A61P31/22 ,  A61P35/00

CPC分类号： A61K39/4611 ,  C12N5/0636 ,  A61K39/464838 ,  A61P31/22 ,  A61P35/00 ,  A61K39/464449 ,  A61K39/46444 ,  A61K39/464402 ,  A61K39/464452 ,  C12N2502/1121 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  A61K2239/57 ,  A61K2239/26

摘要： The invention described herein provide Kaposi Sarcoma-Associated Herpesvirus (KSHV) oncoprotein antigens and epitopes for expanding antigen-specific T cells. Such expanded T cells are useful for, e.g., in allogeneic or “off-the-shelf” adoptive T cell therapy.

公开(公告)号：US20230407254A1

公开(公告)日：2023-12-21

申请号：US18331098

申请日：2023-06-07

申请人： CREATIVE MEDICAL TECHNOLOGIES, INC.

发明人： Thomas ICHIM ,  Amit PATEL ,  Courtney BARTLETT

IPC分类号： C12N5/0783

CPC分类号： C12N5/0636 ,  C12N2506/45 ,  C12N2501/2307 ,  C12N2501/2302 ,  C12N2501/999 ,  C12N2500/98

摘要： Disclosed are novel cellular compositions of matter and treatment means for generation of universal donor regenerative T cells by exposure to mesenchymal stem cells or supernatant derived thereof. In one embodiment, regenerative T cells are created by differentiation of pluripotent stem cells in the presence of supernatant generated from activated mesenchymal stem cell population. The invention provides for creation of T cells which are capable of endowing regenerative activity, and/or anti-inflammatory, and/or angiogenic activity.

公开(公告)号：US20230390393A1

公开(公告)日：2023-12-07

申请号：US18033335

申请日：2021-11-02

申请人： Miltenyi Biotec B.V. & Co KG

发明人： Olaf HARDT ,  Andreas BOSIO

IPC分类号： A61K39/00 ,  C07K14/725 ,  C07K16/30 ,  C07K16/18 ,  C07K16/28 ,  C07K14/705 ,  A61P35/00 ,  C12N5/0783

CPC分类号： A61K39/464468 ,  C07K14/7051 ,  C07K16/3023 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/28 ,  C07K16/2896 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  A61K39/4631 ,  A61K39/4611 ,  A61P35/00 ,  C12N5/0636 ,  C07K2319/03 ,  C07K2319/02 ,  C12N2501/2307 ,  C12N2501/2315

摘要： The present invention is directed to a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for MSLN in combination with one or more antigen binding domains specific for an antigen selected from the group consisting of CLA, CD66c, TSPAN8 and CD318; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

公开(公告)号：US20230357721A1

公开(公告)日：2023-11-09

申请号：US18354308

申请日：2023-07-18

申请人： Baylor College of Medicine ,  Wilson Wolf Manufacturing

发明人： Ann Marie Leen ,  Ulrike Gerdemann ,  Cliona M. Rooney ,  Juan F. Vera Valdes ,  John R. Wilson

IPC分类号： C12N5/0783 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K39/245

CPC分类号： C12N5/0638 ,  C12N5/0636 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/155 ,  A61K39/245 ,  C12N2501/23 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/572 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2502/11

摘要： The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.